Trial · NCT03684772
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete clinical clearance (CCC) per field | Day 42 | |
| Primary | Change in AK-FAS (AK field assessment scale) | Day 42 | AK Grade 0-IV, the higher the number the more % area covered by AK |
| Primary | Investigator global score (IGS) of each field | Day 126 | This is a 7 point scale from -2 (significantly worse) to +4 (completely cured), higher values represent a better outcome |
| Primary | Evolution of one assigned target lesion in the field, assessed by dermoscopy | Day 126 | assessing erythema, scaling, pigmentation, and follicular plug |
| Primary | Field morphology | Day 126 | Change in lesion count per field |
| Primary | Standardized photography with Canfield VISIA or 2D photography and with Antera 3D camera | Day 126 | |
| Primary | Biopsy biomarker | Day 126 | Analysis will be prerformed for the following biomarker: IFN-a. IFN-g, Ki-67 |
| Primary | Biopsy biomarker | Day 126 | Analysis will be prerformed for the following biomarker: IFN-g |
| Primary | Biopsy biomarker | Day 126 | Analysis will be prerformed for the following biomarker: Ki-67 |
| Primary | Biopsy biomarker | Day 126 | Analysis will be prerformed for the following biomarker: p53 |
| Primary | Biopsy biomarker | Day 126 | Analysis will be prerformed for the following biomarker: MCM7(minichromosome maintenance protein 7) |
| Primary | Biopsy biomarker | Day 126 | Analysis will be prerformed for the following biomarker:putrescene |
| Primary | Biopsy biomarker | Day 126 | Analysis will be prerformed for the following biomarker: spermidine |
| Primary | Biopsy biomarker | Day 126 | Analysis will be prerformed for the following biomarker: beta HPV types 5,8,15,20,24,38 |
| Primary | Skin swab markers | Day 126 | Swab analysis will be performed for beta HPV types 5,8,15,20,24,38. |
| Secondary | Adverse events collected throughout the study | Day 126 | |
| Secondary | 12-Lead ECGs performed at Screening and End of Study | Day 126 | The following component will be assessed: Heart Rate (bpm |
| Secondary | 12-Lead ECGs performed at Screening and End of Study | Day 126 | The following component will be assessed: PR |
| Secondary | 12-Lead ECGs performed at Screening and End of Study | Day 126 | The following component will be assessed: QRS |
| Secondary | 12-Lead ECGs performed at Screening and End of Study | Day 126 | The following component will be assessed: QT |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03684772/registered